Matt S Anderson
Overview
Explore the profile of Matt S Anderson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
353
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhardwaj R, Malatesta J, Madonia J, Anderson M, Morris B, Matschke K, et al.
Clin Transl Sci
. 2024 Nov;
17(12):e70048.
PMID: 39602316
Zavegepant is a calcitonin gene-related peptide receptor antagonist for acute migraine treatment. This Phase I, open-label, fixed-sequence study evaluated the effects of itraconazole (a strong cytochrome P450 3A4 [CYP3A4] and...
2.
Bhardwaj R, Donohue M, Madonia J, Matschke K, Anderson M, Morris B, et al.
Headache
. 2024 Oct;
65(2):315-325.
PMID: 39364589
Objective: To evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) interactions between zavegepant and sumatriptan in healthy adults. Background: Zavegepant is a high-affinity, selective, small-molecule calcitonin gene-related peptide receptor antagonist administered...
3.
Bhardwaj R, Donohue M, Madonia J, Anderson M, Matschke K, Bertz R, et al.
Clin Transl Sci
. 2024 Sep;
17(10):e70015.
PMID: 39348235
Zavegepant, a high-affinity, selective, small-molecule calcitonin gene-related peptide receptor antagonist, is approved as a nasal spray for acute treatment of migraine in adults. This phase I, open-label, single-center, single-period, nonrandomized...
4.
Schurmann D, Huser A, Pfafflin F, Cilissen C, De Lepeleire I, Larson P, et al.
AIDS Res Hum Retroviruses
. 2024 Sep;
41(1):11-19.
PMID: 39291814
To assess the antiviral activity, pharmacokinetics, and safety of MK-6186 in HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI)-naïve, HIV-1-infected male participants. Double-blind, randomized, two-panel study. In 2 sequential panels, 18 participants...
5.
Hughes J, Bertz R, Bhardwaj R, Donohue M, Madonia J, Anderson M, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 May;
13(6):1044-1054.
PMID: 38812357
Zavegepant is a novel gepant administered as a nasal spray approved in the United States at a 10 mg dose for the acute treatment of migraine with or without aura...
6.
Croop R, Bhardwaj R, Anderson M, Matschke K, Hould J, Bertz R, et al.
Cephalalgia
. 2024 Feb;
44(2):3331024231219505.
PMID: 38366390
Background: Rimegepant is an orally administered small molecule calcitonin gene-related peptide receptor antagonist indicated for the acute and preventive treatment of migraine. Methods: Two single-center, phase 1, open-label, randomized bioequivalence...
7.
Bhardwaj R, Collins J, Stringfellow J, Madonia J, Anderson M, Finley J, et al.
Clin Pharmacol Drug Dev
. 2022 Mar;
11(7):889-897.
PMID: 35304977
Rimegepant (Nurtec ODT)-an orally administered, small-molecule calcitonin gene-related peptide receptor antagonist indicated for the acute and preventive treatment of migraine-is a substrate for both the P-glycoprotein and breast cancer resistance...
8.
Baker T, Croop R, Kamen L, Price P, Stock D, Ivans A, et al.
Breastfeed Med
. 2022 Jan;
17(3):277-282.
PMID: 35049333
Investigate whether rimegepant-an oral small molecule calcitonin gene-related peptide receptor antagonist for the treatment of migraine-is excreted in human milk after a single 75 mg dose and characterize its concentration-time...
9.
Li W, Wang Y, Lohith T, Zeng Z, Tong L, Mazzola R, et al.
Sci Transl Med
. 2022 Jan;
14(627):eabg3684.
PMID: 35020407
Positron emission tomography (PET) ligands play an important role in the development of therapeutics by serving as target engagement or pharmacodynamic biomarkers. Here, we describe the discovery and translation of...
10.
Qureshi I, Lovegren M, Wirtz V, Larouche R, Tanguay M, Anderson M, et al.
Clin Pharmacol Drug Dev
. 2019 Oct;
9(4):476-485.
PMID: 31610101
Orally administered riluzole extends survival in patients with amyotrophic lateral sclerosis, although it has significant shortcomings (eg, adverse events, dysphagic patients) that limit its utility. BHV-0223 is a Zydis-based orally...